Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade

(2016) Haidong Tang et al.   CANCER CELL

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Blinatumomab: First Global Approval

(2015) Mark Sanford   DRUGS

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

FDA approves first bispecific

(2015) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment

(2015) Thomas F. Gajewski   SEMINARS IN ONCOLOGY

Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody

(2015) Mahiuddin Ahmed et al.   OncoImmunology

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

(2015) Margaret K. Callahan et al.   Frontiers in Oncology

HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development

(2014) J C Singh et al.   BRITISH JOURNAL OF CANCER

Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells

(2014) T. T. Junttila et al.   CANCER RESEARCH

HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma

(2014) Netanya I. Pollock et al.   CLINICAL CANCER RESEARCH

Regulatory T cells in cancer immunotherapy

(2014) Hiroyoshi Nishikawa et al.   CURRENT OPINION IN IMMUNOLOGY

Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex

(2014) S. M. Cheal et al.   MOLECULAR CANCER THERAPEUTICS

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications

(2014) C. Marcela Diaz-Montero et al.   SEMINARS IN ONCOLOGY

Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody

(2014) H. Xu et al.   Cancer Immunology Research

Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression

(2014) Damya Laoui et al.   Frontiers in Immunology

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

(2013) Allan Lipton et al.   BREAST CANCER RESEARCH AND TREATMENT

Biomarkers of drugs targeting HER-family signalling in cancer

(2013) Filippo Montemurro et al.   JOURNAL OF PATHOLOGY

Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA

(2013) David A. Nathanson et al.   SCIENCE

The two sides of HER2/neu: immune escape versus surveillance

(2013) Barbara Seliger et al.   TRENDS IN MOLECULAR MEDICINE

Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group

(2012) David Ebb et al.   JOURNAL OF CLINICAL ONCOLOGY

Dual targeting strategies with bispecific antibodies

(2012) Roland Kontermann   mAbs

Ipilimumab in advanced melanoma

(2012) Alberto Farolfi et al.   MELANOMA RESEARCH

MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells

(2012) C.-T. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets

(2012) Maxim Yankelevich et al.   PEDIATRIC BLOOD & CANCER

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

(2012) David H. Munn et al.   TRENDS IN IMMUNOLOGY

Engraftment of peripheral blood mononuclear cells from systemic lupus erythematosus and antiphospholipid syndrome patient donors into BALB-RAG-2−/−IL-2Rγ−/− mice: A promising model for studying human disease

(2011) Danieli Andrade et al.   ARTHRITIS AND RHEUMATISM

Targeting T Cells with Bispecific Antibodies for Cancer Therapy

(2011) Lawrence G. Lum et al.   BIODRUGS

Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma

(2011) N Rainusso et al.   CANCER GENE THERAPY

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

(2011) Devika Gajria et al.   Expert Review of Anticancer Therapy

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression

(2009) Nabil Ahmed et al.   MOLECULAR THERAPY

A modular IgG-scFv bispecific antibody topology

(2009) Kelly Davis Orcutt et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Use of humanized severe combined immunodeficient mice for human vaccine development

(2008) Gloria C Koo et al.   Expert Review of Vaccines